NHEK, STAT3 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation |
| NHEK-0019 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation | Western blot | IL-17 / OSM / TNF- alpha | |
NHEK, STAT3 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation |
| NHEK-0020 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation | Western blot | Oncostatin M | |
NHEK, STAT3 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation |
| NHEK-0021 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation | Flow cytometry (CBA) | IL-17 / OSM / TNF- alpha | |
NHEK, STAT3 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation / translocation |
| NHEK-0022 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation / translocation | Immunofluorescence | IL-17 / OSM / TNF- alpha | |
NHEK, STAT3 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation / translocation |
| NHEK-0023 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation / translocation | Immunofluorescence | OSM | |
NHEK, p38 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | p38 phosphorylation |
| NHEK-0024 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | p38 phosphorylation | Western blot | IL-17 / OSM / TNF- alpha | |
NHEK, p38 activation (IL-1 alpha stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | p38 phosphorylation |
| NHEK-0025 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | p38 phosphorylation | Western blot | IL-1 alpha | |
NHEK, p38 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | p38 phosphorylation |
| NHEK-0026 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | p38 phosphorylation | Flow cytometry (CBA) | IL-17 / OSM / TNF- alpha | |
NHEK, ERK1/2 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | ERK1/2 phosphorylation |
| NHEK-0027 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | ERK1/2 phosphorylation | Western blot | IL-17 / OSM / TNF- alpha | |
NHEK, ERK1/2 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | ERK1/2 phosphorylation |
| NHEK-0028 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | ERK1/2 phosphorylation | Western blot | Oncostatin M | |
NHEK, JNK activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | JNK phosphorylation |
| NHEK-0029 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | JNK phosphorylation | Western blot | IL-17 / OSM / TNF- alpha | |
NHEK, JNK activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | JNK phosphorylation |
| NHEK-0030 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | JNK phosphorylation | Western blot | Oncostatin M | |
NHEK, JNK activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | JNK phosphorylation |
| NHEK-0031 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | JNK phosphorylation | Flow cytometry (CBA) | IL-17 / OSM / TNF- alpha | |
NHEK, STAT3 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT3 phosphorylation |
| NHEK-0041 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT3 phosphorylation | Flow cytometry (CBA) | OSM | |
NHEK, ERK1/2 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | ERK1/2 phosphorylation |
| NHEK-0042 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | ERK1/2 phosphorylation | Flow cytometry (CBA) | IL-17 / OSM / TNF- alpha | |
NHEK, ERK1/2 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | ERK1/2 phosphorylation |
| NHEK-0043 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | ERK1/2 phosphorylation | Flow cytometry (CBA) | OSM | |
NHEK, cytokine/chemokine release (IL-1 alpha stimulation)| Type of assay | Cytokines/chemokines | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | IL-8 release, CCL20 release |
| NHEK-0167 | Psoriasis, Psoriasis | Cytokines/chemokines | Epidermal keratinocytes (NHEK) | Human | IL-8 release, CCL20 release | ELISA / EIA | IL-1 alpha | |
T cells, cytokine release (anti-CD3/anti-CD28 stimulation)| Type of assay | Th17 polarity - Cytokines | | Biological model | PBMCs | | Species | Human | | Endpoint | IL-17 release, or other Th17 cytokines |
| PBMC-0010 | T lymphocytes: anti-inflammatory effects/immunosuppression, Psoriasis, Psoriasis, T lymphocytes: anti-inflammatory effects/immunosuppression - cell-mediated and humoral immunity modulation | Th17 polarity - Cytokines | PBMCs | Human | IL-17 release, or other Th17 cytokines | ELISA / EIA | Anti-CD3 / Anti-CD28 | |
Psoriatic T cell line, cytokine release (anti-CD3/anti-CD28 stimulation)| Type of assay | Th17 polarity - Cytokines | | Biological model | T cells derived from psoriatic lesions | | Species | Human | | Endpoint | IL-17 release, or other Th17 cytokines |
| TLPSO-0001 | T lymphocytes: anti-inflammatory effects/immunosuppression, Psoriasis, Psoriasis, T lymphocytes: anti-inflammatory effects/immunosuppression - cell-mediated and humoral immunity modulation | Th17 polarity - Cytokines | T cells derived from psoriatic lesions | Human | IL-17 release, or other Th17 cytokines | ELISA / EIA | Anti-CD3 / Anti-CD28 | |
